|
|
Volumn 6, Issue 3, 2005, Pages 136-
|
|
Bevacizumab adds survival benefit in colorectal cancer
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BEVACIZUMAB;
FLUOROURACIL;
FOLINIC ACID;
IRINOTECAN;
OXALIPLATIN;
VASCULOTROPIN;
CANCER COMBINATION CHEMOTHERAPY;
CANCER MORTALITY;
CANCER RELAPSE;
CANCER SURVIVAL;
CLINICAL TRIAL;
COLORECTAL CANCER;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG TARGETING;
HEALTH STATUS;
HUMAN;
MAJOR CLINICAL STUDY;
METASTASIS POTENTIAL;
NEUROPATHY;
NOTE;
PATIENT SELECTION;
PHASE 3 CLINICAL TRIAL;
PRIORITY JOURNAL;
TREATMENT OUTCOME;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
COLORECTAL NEOPLASMS;
HUMANS;
SURVIVAL RATE;
|
|
EID: 14544308313
PISSN: 14702045
EISSN: None
Source Type: Journal
DOI: 10.1016/S1470-2045(05)01757-2 Document Type: Note |
|
Times cited : (9)
|
|
References (0)
|